Phase 1a Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamic Effects of AKB 4924 in Healthy Male Volunteers
Phase of Trial: Phase I
Latest Information Update: 21 Mar 2017
At a glance
- Drugs AKB 4924 (Primary)
- Indications Inflammatory bowel diseases
- Focus Adverse reactions
- Sponsors Aerpio Therapeutics
- 15 Mar 2017 Status changed from active, no longer recruiting to completed.
- 17 Jan 2017 Status changed from recruiting to active, no longer recruiting.
- 26 Sep 2016 According to an Aerpio Therapeutics media release, first patient was dosed and preliminary results from this study are expected in Q4 2016.